Results 191 to 200 of about 63,510 (311)

HLA Class II Histocompatibility Antigen, DM Beta Chain [PDF]

, 2020
openaire   +1 more source

Autophagy Inhibition by Fangji Huangqi Decoction Enhances Tumor Immunogenicity and Potentiates PD‐1 Blockade

Cancer Science, EarlyView.
In tumor cells, MHC‐I is typically degraded through autophagy, leading to reduced antigen presentation. However, Fangji Huangqi Decoction (FJHQ), acting as an autophagy inhibitor, suppresses lysosomal acidification, which in turn inhibits the degradation of MHC‐I. This results in increased surface expression of MHC‐I on tumor cells.
Yuxiao Jiang, Shiji Zeng, Dingye Wang, Junbo Jiang, Zhenzhen Li, Jingbi Li, Dan Chen, Xu Zhao, Zheng Ying, Yuehua Deng, Qianwei Cai, Silin Mai, Jiayi Zheng, Qiaohong Yang, Fang Liu, Biaoyan Du, Jianyong Xiao, Xiaoyi Liu, Kun Wang   +18 more
wiley   +1 more source

Nomenclature for Factors of the HLA System, 2026. [PDF]

HLA
Marsh SGE, Osoegawa K, Bodmer WF, Bontrop RE, Carrington MN, Erlich HA, Heidt S, Holdsworth R, Mayr WR, Maiers M, Parham P, Petersdorf EW, Robinson J, Trowsdale J, Fernández-Viña M.   +14 more
europepmc   +1 more source

Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer

Cancer Science, EarlyView.
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo, Yuqian Feng, Jiamin Lu, Nuerbiye Abudurexiti, Xinlei Zhou, Mengfan Wei, Song Zheng   +6 more
wiley   +1 more source

A major histocompatibility complex (MHC) class II molecule that binds the same viral pathogen peptide with both nonamer and decamer core sequences for presentation to T cells. [PDF]

J Virol
Goryanin A, Cook AG, Behboudi S, Kaufman J, Halabi S.   +4 more
europepmc   +1 more source

Irradiated Liver Cancer Cell Vaccine Transfected With GM‐CSF Induces Specific and Long‐Lasting Anti‐tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM‐CSF

Cell Proliferation, EarlyView.
Song et al. developed an mGM‐CSF‐loaded, liver cancer cell‐based vaccine that potently activated dendritic cells and elicited tumour‐specific T cell responses. Mechanistically, radiation‐induced oxidative damage to mitochondrial DNA in cancer cells triggers the cGAS‐STING pathway in DCs, which synergizes with mGM‐CSF‐driven JAK2‐STAT3 signalling to ...
Zhiruo Song, Yujie Jiang, Yu Zhang, Danyi Ao, Chunjun Ye, Xiya Huang, Yingqiong Zhou, Hanle Yang, Ruolan Xia, Jiayuan Ai, Dandan Wan, Aiping Tong, Yuquan Wei, Xuemei He, Aqu Alu, Xiawei Wei   +15 more
wiley   +1 more source

Association Between Baseline Anti-HLA (Class I and II) and Anti-MICA Antibodies and Inflammatory Cell Infiltrates in Grafted Bone After Maxillary Sinus Floor Augmentation: An Exploratory Secondary Histological Study. [PDF]

Life (Basel)
Dominiak S, Dominiak M, Hadzik J, Ciszyński M, Kepinska M, Banasik M, Piotrowska A, Dzięgiel P, Gedrange T, Baranowska A, Kubasiewicz-Ross P.   +10 more
europepmc   +1 more source

Impact of G‐CSF on Donor TCR Clonal Diversity and T Cell Function During Donor HSC Mobilisation

Cell Proliferation, EarlyView.
In this study, we found that G‐CSF mobilisation caused a reduction in TCR clonal diversity and down‐regulation of T‐cell function in donors. This may be one of the reasons for the low incidence of GVHD mediated by G‐CSF after allo‐HSCT. Source: Created in BioRender. Li https://BioRender.com/otownki.
Xinye Li, Zhixi Chen, Jie Chen, Xingwei Zhang, Jiamian Zheng, Zirui Liu, Meixue Pan, Yue Li, Bo Yu, Shaohua Chen, Jing Lai, Xianfeng Zha, Liye Zhong, Yikai Zhang, Yangqiu Li   +14 more
wiley   +1 more source

HLA Class II Histocompatibility Antigen, DO Beta Chain [PDF]

, 2020
openaire   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source